Adlai Nortye Ltd. (ANL)

Adlai Nortye Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Adlai Nortye Ltd. (ANL) is a Biotechnology company based in KY with a market capitalization of $690M. Free cash flow was negative at -$33.7M. This page tracks ANL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

KY · 123 employees · IPO Sep 29, 2023

Valuation

Valuation & price

$12.29as of May 26, 2026· -26.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$0.8852-week range$16.60

Loading valuation history…

Fundamentals

Key fundamentals

$690M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$33.7M

Free cash flow (USD)

$2.6M

Net debt

0.1%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

$0$5M

Free cash flow by year

2019 → 2025

-$15.1M-$33.7M

Gross margin by year

2021 → 2025

100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

Insider buys · 90 days

Insider sells · 90 days

Earnings

Last report: 20-F filed Apr 10, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

6-K filingJul 16, 2026Filing
Clinical Trial Update
Insider sellMay 21, 2026Filing
Insider Sell $132LU YANG · Director, CEO, 10% Owner · $131.8
6-K filingApr 16, 2026Filing
Securities Purchase Agreement
Annual reportApr 10, 2026Filing
20-F Filed
Annual reportApr 1, 2026Filing
Annual Report Filed

Questions

Frequently asked questions

What is Adlai Nortye Ltd.'s market cap?

Adlai Nortye Ltd. (ANL) has a market capitalization of $690M.

What is ANL's P/E ratio?

A meaningful P/E ratio is not available for ANL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying ANL stock?

SEC Form 4 filings show no open-market insider buys at Adlai Nortye Ltd. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

ACRS

Aclaris Therapeutics, Inc.

$686.2M

OCS

Oculis Holding AG

$683.7M

ESPR

Esperion Therapeutics, Inc.

$661.1M

RIGL

Rigel Pharmaceuticals, Inc.

$727.3M

ZVRA

Zevra Therapeutics, Inc.

$736M

MDXG

MiMedx Group, Inc.

$643.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.